1-833-ZEPOSIA
ZEPOSIA is a once-daily pill for adults with moderate to severe ulcerative colitis (UC).
Take as directed by your doctor if certain liver problems exist.
ZEPOSIA is a once-daily pill for adults with moderate to severe ulcerative colitis (UC).
Take as directed by your doctor if certain liver problems exist.
ZEPOSIA was proven effective in clinical studies. For more information about how the study was designed, click here
Achieve lasting remission with ZEPOSIA (fewer symptoms and reduced inflammation seen during a colonoscopy at 1 year).*
Reduced rectal bleeding and fewer trips to the bathroom are possible in as early as 2 weeks.
You can experience
ZEPOSIA was studied in a 1-year clinical study where all participants (ZEPOSIA: 429, placebo: 216) were evaluated at 10 weeks. Those who had achieved symptom improvement at 10 weeks were then able to continue (ZEPOSIA: 230, placebo: 227) and be evaluated at 1 year. Learn more about the study
Reduced rectal bleeding and fewer trips to the bathroom
48% experienced symptom improvement Symptom improvement or “clinical response” was defined as an improvement in symptoms (stool frequency and rectal bleeding) and/or the clinical results of an endoscopy. “Clinical response” can be different for everyone because it is based on the severity of your UC when you start taking a certain treatment.
(vs 26% on placebo)
18% were in remission Remission was defined as:
No rectal bleeding
Reduction of stool frequency to normal, or one or two stools more than normal
Improvement in how the intestinal lining looked during an endoscopy, representing mild or inactive disease in the colon
(vs 6% on placebo)
Only patients who achieved symptom improvement at 10 weeks continued and were evaluated at the 1-year mark.
60% experienced symptom improvement Symptom improvement or “clinical response” was defined as an improvement in symptoms (stool frequency and rectal bleeding) and/or the clinical results of an endoscopy. “Clinical response” can be different for everyone because it is based on the severity of your UC when you start taking a certain treatment.
(vs 41% on placebo)
37% were in remission Remission was defined as:
No rectal bleeding
Reduction of stool frequency to normal, or one or two stools more than normal
Improvement in how the intestinal lining looked during an endoscopy, representing mild or inactive disease in the colon
(vs 19% on placebo)
ZEPOSIA can help with intestinal healing by reducing inflammation on and below the surface of the colon lining.‡
People taking ZEPOSIA were nearly 2 times more likely to achieve lasting
ZEPOSIA has a well-established safety profile across 4 clinical trials and 2 conditions.§ See the side effects that were reported in the UC clinical trials.
Explore safetyZEPOSIA was studied in a 1-year clinical study where all participants (ZEPOSIA: 429, placebo: 216) were first evaluated at 10 weeks. Those who had achieved symptom improvement at 10 weeks were then able to continue in the study (ZEPOSIA: 230, placebo: 227) and be evaluated at the 1-year mark.
Patients were to be receiving treatment with an oral 5-ASA and/or steroids to enter the study.
The study was randomized and placebo controlled. This means participants were randomly placed into 1 of 2 groups: those taking ZEPOSIA and those taking a placebo pill (not ZEPOSIA).